Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 39Lymphoma 27Multiple Myeloma 24Colorectal Neoplasms 20Leukemia, Myeloid, Acute 18Melanoma 13Lung Neoplasms 13Prostatic Neoplasms 12Pancreatic Neoplasms 12Ovarian Neoplasms 12Breast Neoplasms 11Sarcoma 10Triple Negative Breast Neoplasms 9Lymphoma, Non-Hodgkin 9Fallopian Tube Neoplasms 9Burkitt Lymphoma 9Urinary Bladder Neoplasms 8Neuroblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Glioma 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Myelodysplastic Syndromes 7Lymphoma, Follicular 7Endometrial Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5

Interventions

berzosertib 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Clinical Stage III Gastric Cancer AJCC v8 × Biopsy × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡